Jan 27, 2021
- Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales
- Sales growth of 28.7 percent; organic sales growth of 28.4 percent
- GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent
- Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020
- R&D pipeline continues to be highly productive, delivering ground-breaking innovations and a steady cadence of important new products across all business areas
- Issues 2021 EPS growth forecast of more than 35 percent